A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled "NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma." Researchers Andrea ...

Multiple myeloma is a cancer in which plasma cells, which normally produce antibodies, multiply uncontrollably in the bone marrow. There is currently no cure. However, various therapies can stabilize ...

Osaka, Japan – Vaccine effectiveness relies on creating a strong antibody response that can be reactivated to fight future infections. Now, researchers from Japan report that antibody-producing cells ...

This article and associated images are based on a poster originally authored by Mette Juul Jacobsen, Anastasios Glaros, Abrahan Hernandez-Hernandez, Anja Mezger, Tina Friis, and Peter Mouritzen and ...

Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, potentially opening a path to new treatments for a condition that kills 80% of ...

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth ...

Researchers reveal critical mechanism behind idiopathic pulmonary fibrosis. Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...